Literature DB >> 28841363

Tocilizumab (Actemra).

Martin Sheppard1, Faidra Laskou1, Philip P Stapleton1, Shahryar Hadavi1, Bhaskar Dasgupta1.   

Abstract

Tocilizumab (TCZ), is a recombinant humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody which has a main use in the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis (sJIA) and polyarticular juvenile idiopathic arthritis (pJIA). This article provides an overview of TCZ including looking into the past at the discovery of interleukin-6 (IL-6) as a pro-inflammatory cytokine. It also looks at how tocilizumab was developed, manufactured and tested to ensure both safety and efficacy in a human population. The article then explores the advantages and disadvantages of using TCZ when compared to other biologics approved in RA, sJIA and pJIA and finally looks ahead to the future and the emerging role of IL-6 and its blockade by TCZ as a treatment for giant cell arteritis (GCA), polymyalgia rheumatica (PMR) and large vessel vasculitis (LVV).

Entities:  

Keywords:  giant cell arteritis; interleukin-6; monoclonal antibody; rheumatoid arthritis; tocilizumab; vasculitis

Mesh：

Substances：

Year:  2017        PMID： 28841363      PMCID： PMC5612212          DOI： 10.1080/21645515.2017.1316909

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  69 in total

1.  Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease.

Authors:  Masahiro Iwamoto; Hiroyuki Nara; Daisuke Hirata; Seiji Minota; Norihiro Nishimoto; Kazuyuki Yoshizaki
Journal:  Arthritis Rheum       Date:  2002-12

2.  Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica.

Authors:  Keisuke Hagihara; Ichiro Kawase; Toshio Tanaka; Tadamitsu Kishimoto
Journal:  J Rheumatol       Date:  2010-05       Impact factor: 4.666

3.  Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

Authors:  Gabor G Illei; Yuko Shirota; Cheryl H Yarboro; Jimmy Daruwalla; Edward Tackey; Kazuki Takada; Thomas Fleisher; James E Balow; Peter E Lipsky
Journal:  Arthritis Rheum       Date:  2010-02

Review 4.  Human monoclonal antibody production. Current status and future prospects.

Authors:  K James; G T Bell
Journal:  J Immunol Methods       Date:  1987-06-26       Impact factor: 2.303

5.  Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review.

Authors:  Noémie Abisror; Arsene Mekinian; Christian Lavigne; Marie-Anne Vandenhende; Michael Soussan; Olivier Fain
Journal:  Autoimmun Rev       Date:  2013-06-29       Impact factor: 9.754

6.  Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.

Authors:  Juan J Gómez-Reino; Loreto Carmona; Vicente Rodríguez Valverde; Emilio Martín Mola; Maria Dolores Montero
Journal:  Arthritis Rheum       Date:  2003-08

7.  Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.

Authors:  Merete Lund Hetland; Ib Jarle Christensen; Ulrik Tarp; Lene Dreyer; Annette Hansen; Ib Tønder Hansen; Gina Kollerup; Louise Linde; Hanne M Lindegaard; Uta Engling Poulsen; Annette Schlemmer; Dorte Vendelbo Jensen; Signe Jensen; Gisela Hostenkamp; Mikkel Østergaard
Journal:  Arthritis Rheum       Date:  2010-01

8.  Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor.

Authors:  Christoph Garbers; Wolfgang Thaiss; Gareth W Jones; Georg H Waetzig; Inken Lorenzen; Florence Guilhot; Rami Lissilaa; Walter G Ferlin; Joachim Grötzinger; Simon A Jones; Stefan Rose-John; Jürgen Scheller
Journal:  J Biol Chem       Date:  2011-10-11       Impact factor: 5.157

9.  Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.

Authors:  N Nishimoto; N Miyasaka; K Yamamoto; S Kawai; T Takeuchi; J Azuma
Journal:  Ann Rheum Dis       Date:  2008-11-19       Impact factor: 19.103

10.  Tocilizumab in refractory rheumatoid arthritis: long-term efficacy, safety, and tolerability beyond 2 years.

Authors:  Ziad Farah; Sabreen Ali; Fiona Price-Kuehne; Charles G Mackworth-Young
Journal:  Biologics       Date:  2016-03-22
View more
  56 in total

1.  Effect of tocilizumab, an interleukin-6 inhibitor, on early stage streptozotocin-induced diabetic nephropathy in rats.

Authors:  Aly M Abdelrahman; Yousuf Al Suleimani; Asem Shalaby; Mohammed Ashique; Priyadarsini Manoj; Badreldin H Ali
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-04-25       Impact factor: 3.000

Review 2.  Lupus, Silica, and Dietary Omega-3 Fatty Acid Interventions.

Authors:  Kathryn A Wierenga; Jack R Harkema; James J Pestka
Journal:  Toxicol Pathol       Date:  2019-11-14       Impact factor: 1.902

Review 3.  Cardiovascular Disease Risk in Older Adults and Elderly Patients with Rheumatoid Arthritis: What Role Can Disease-Modifying Antirheumatic Drugs Play in Cardiovascular Risk Reduction?

Authors:  Alvin Lee Day; Jasvinder A Singh
Journal:  Drugs Aging       Date:  2019-06       Impact factor: 3.923

4.  A BRIEF SYNOPSIS OF MONOCLONAL ANTIBODY FOR THE TREATMENT OF VARIOUS GROUPS OF DISEASES.

Authors:  Aselin Puthenpurail; Hinal Rathi; Surya M Nauli; Ahmmed Ally
Journal:  World J Pharm Pharm Sci       Date:  2021-11

5.  Implications for Systemic Approaches to COVID-19: Effect Sizes of Remdesivir, Tocilizumab, Melatonin, Vitamin D3, and Meditation.

Authors:  Ryan D Castle; Michelle A Williams; William C Bushell; J Adam Rindfleisch; Christine Tara Peterson; James Marzolf; Kimberly Brouwer; Paul J Mills
Journal:  J Inflamm Res       Date:  2021-09-22

Review 6.  A new era for giant cell arteritis.

Authors:  H S Lyons; V Quick; A J Sinclair; S Nagaraju; S P Mollan
Journal:  Eye (Lond)       Date:  2019-10-03       Impact factor: 3.775

7.  Early Adaptation of Colorectal Cancer Cells to the Peritoneal Cavity Is Associated with Activation of "Stemness" Programs and Local Inflammation.

Authors:  Jorge Barriuso; Raghavendar T Nagaraju; Shreya Belgamwar; Bipasha Chakrabarty; George J Burghel; Helene Schlecht; Lucy Foster; Elaine Kilgour; Andrew J Wallace; Michael Braun; Caroline Dive; D Gareth Evans; Robert G Bristow; Mark P Saunders; Sarah T O'Dwyer; Omer Aziz
Journal:  Clin Cancer Res       Date:  2020-11-30       Impact factor: 12.531

Review 8.  Role of Inflammatory Cytokines in COVID-19 Patients: A Review on Molecular Mechanisms, Immune Functions, Immunopathology and Immunomodulatory Drugs to Counter Cytokine Storm.

Authors:  Ali A Rabaan; Shamsah H Al-Ahmed; Javed Muhammad; Amjad Khan; Anupam A Sule; Raghavendra Tirupathi; Abbas Al Mutair; Saad Alhumaid; Awad Al-Omari; Manish Dhawan; Ruchi Tiwari; Khan Sharun; Ranjan K Mohapatra; Saikat Mitra; Muhammad Bilal; Salem A Alyami; Talha Bin Emran; Mohammad Ali Moni; Kuldeep Dhama
Journal:  Vaccines (Basel)       Date:  2021-04-29

Review 9.  Emergent Drug and Nutrition Interactions in COVID-19: A Comprehensive Narrative Review.

Authors:  Duygu Ağagündüz; Menşure Nur Çelik; Merve Esra Çıtar Dazıroğlu; Raffaele Capasso
Journal:  Nutrients       Date:  2021-05-04       Impact factor: 5.717

Review 10.  Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis.

Authors:  Donovan A McGrowder; Fabian Miller; Melisa Anderson Cross; Lennox Anderson-Jackson; Sophia Bryan; Lowell Dilworth
Journal:  Diseases       Date:  2021-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.